


























































published: 19 December 2013
doi: 10.3389/fped.2013.00047
Neurodevelopmental outcomes after pediatric cardiac
ECMO support
Constantinos Chrysostomou1*,Timothy Maul 2, Patrick M. Callahan3, Khoa Nguyen3, Steven Lichtenstein3,
Emma G. Coate4,Victor O. Morell 2 and PeterWearden2
1 Critical Care Medicine, Cardiac Intensive Care, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA
2 Cardiothoracic Surgery, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA
3 Department of Anesthesiology, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA
4 Dietrich School of Arts and Sciences, University of Pittsburgh, Pittsburgh, PA, USA
Edited by:
Cecile Tissot, University Children’s
Hospital, Switzerland
Reviewed by:
C. Alberto Figueroa, King’s College
London, UK




Care Medicine, Cardiac Intensive
Care, Children’s Hospital of Pittsburgh
of UPMC, 4401 Penn Avenue,
Pittsburgh, PA 15224, USA
e-mail: chrycx@chp.edu
Purpose: To characterize the neurodevelopmental outcomes and identify factors associ-
ated with poor outcomes in pediatric patients undergoing cardiac extracorporeal membrane
oxygenation (ECMO).
Methods: Five year retrospective review, including demographics, cardiac lesion, and sur-
gical complexity, reason for ECMO, ECMO complications, and neurodevelopmental status
at discharge and latest follow-up. Neurodevelopmental status was determined through
the Pediatric Overall Performance Category and Pediatric Cerebral Performance Category
Scales.
Results: Overall ECMO survival was 73% at hospital discharge and 66% a t the latest
follow-up. Most patients underwent cardiopulmonary resuscitation (CPR) (43%), and the
majority (53%) had a significant disease complexity (Aristotle=4). Complications occurred
in 42% of the ECMO runs, of which 12% were intracranial injuries. At hospital discharge,
75% of patients had normal to mild disability, improving to 81% at 2 years follow-up. At hos-
pital discharge, moderate to severe disability was associated with CPR, plasma exchange
or intracranial insults. After discharge, 23% showed improvement in neurologic status
and 4% showed deterioration. Cerebral infarction was the only parameter associated with
deterioration at the later follow-up stage.
Conclusion: Extracorporeal membrane oxygenation was successfully used in children
with cardiac disease with 73 and 66% short and long-term survival respectively. Major-
ity of the survivors had normal to mild neurodevelopmental disability and a significant
portion showed neurologic improvement by the latest follow-up. Nevertheless, despite the
grossly favorable outcomes standardized comprehensive neuropsychological testing is of
paramount importance in all these patients.
Keywords: ECMO, neurodevelopmental outcomes, children, PCPC, E-CPR, cardiac arrest, intracranial hemorrhage,
cerebral infarction
INTRODUCTION
Extracorporeal membrane oxygenation (ECMO) has been the pre-
ferred method of mechanical circulatory support for patients with
acute cardiac and/or respiratory failure since the 1970s. Among
other indications it is frequently used in patients where cardiopul-
monary resuscitation (CPR) is refractory to conventional resus-
citation measures (E-CPR); in patients with low cardiac output
syndrome due to postoperative myocardial dysfunction, primary
myocardial disease, or arrhythmias where further escalation of
therapy outweighs the potential risks of ECMO (LCOS-ECMO);
and in patients who fail to separate from cardiopulmonary bypass
(OR-ECMO). In contrast to our recent publication showing insti-
tutional survival of 73%, the expected average survival rates
hover between 40 and 50% (1, 2). Complications among the
survivors, and in particular neurologic complications, are not
infrequent and maybe related to preceding low cardiac output
events, cardiac arrest, or due to intracranial hemorrhage. Because
the ECMO circuit is a potent activator of the coagulation sys-
tem, systemic anticoagulation is required. Therefore maintaining
a delicate balance between over- and under-anticoagulation is
of paramount importance to prevent hemorrhagic and throm-
boembolic complications, respectively (3–9). According to recent
data from the Extracorporeal Life Support Organization (ELSO)
registry, approximately 20% of all ECMO patients have some
form of neurological complication, and neuroimaging studies per-
formed on ECMO patients have demonstrated a frequency of
abnormal results in 30–50% of cases (2, 10). Similar results have
been obtained for cardiac ECMO patients, with up to 60% hav-
ing moderate to severe neurological impairment (11). However,
the true nature of neurological injury from ECMO patients is
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clouded by the possible pre-ECMO hypoxia and by the underly-
ing anatomic, neurologic, and neurodevelopmental abnormalities
that may occur to as high as 30–50% of patients with congenital
heart defects (CHD) (12–15).
The objective of this study was to assess the short and inter-
mediate term neurodevelopmental outcomes of pediatric cardiac
ECMO survivors and to identify factors associated with worse
outcomes.
MATERIALS AND METHODS
This study was granted exempt status from the University of
Pittsburgh Institutional Review Board and was a retrospective
investigation of ECMO patients in the cardiac intensive care unit
(CICU) at Children’s Hospital of Pittsburgh between January 2006
and December 2010. A team of two cardiac surgeons, three car-
diac intensivists, and four cardiac anesthesiologists were involved
through the study’s 5-year period. Of the 95 patients undergoing
ECMO during this time, 69 (73%) survived to hospital discharge
and thus were the subject of this study. All patients were sup-
ported with veno-arterial ECMO. As part of the institutional
ECMO protocol, all patients received an initial EEG when placed
on ECMO and received daily head ultrasounds for at least 5 days
until decannulation. A detailed description of our ECMO and
E-CPR management protocol, including our protocol to assess
readiness for decannulation, was previously published (1).
NEUROLOGIC STATUS ASSESSMENT
Neurologic assessment was performed using the Pediatric Over-
all Performance Category (POPC) scale and Pediatric Cerebral
Performance Category (PCPC), which assess cognitive impair-
ment and functional (general adaptive or physical) morbidity
after critical illness or injury, respectively (16, 17). Each is a six-
point graded scale of increasing disability from normal function
(score= 1) to death (score= 6) (Tables 1 and 2). As seen in Table 2,
the PCPC scores are incorporated in the POPC scale. Differ-
ences between baseline and discharge POPC and PCPC scores
have been associated with several measures of morbidity includ-
ing ICU length of stay, total hospital charges, and discharge care
needs (16).
The neurologic assessments were obtained at two separate time
points. The first assessment was recorded at hospital discharge
and the second at the time of the latest outpatient follow-up and
when adequate neurodevelopmental information was available in
medical records.
Table 1 | Pediatric cerebral performance category scale.
Score Category Description
1 Normal Normal; at age-appropriate level; school-age child attending regular school classroom
2 Mild disability Conscious, alert, and able to interact at age-appropriate level; school-age child attending regular school classroom,
but grade perhaps not appropriate for age; possibility of mild neurologic deficit
3 Moderate
disability
Conscious; sufficient cerebral function for age-appropriate independent activities of daily life; school-age child
attending special education classroom and/or learning deficit present
4 Severe disability Conscious; dependent on others for daily support because of impaired brain function
5 Coma or
vegetative state
Any degree of coma without the presence of all brain death criteria; unaware, even if awake in appearance, without
interaction with environment; cerebral unresponsiveness and no evidence of cortex function (not aroused by verbal
stimuli); possibility of some reflexive response, spontaneous eye-opening, and sleep-wake cycles
6 Brain death Apnea, areflexia, and/or electroencephalographic silence
Table 2 | Pediatric overall performance category scale.
Score Category Description
1 Good overall performance PCPC=1; healthy, alert, and capable of normal activities of daily life
2 Mild overall disability PCPC=2; possibility of minor physical problem that is still compatible with normal life; conscious and able to
function independently
3 Moderate overall disability PCPC=3; possibility of moderate disability from non-cerebral systems dysfunction alone or with cerebral
system dysfunction; conscious and performs independent activities of daily life but is disabled for competitive
performance in school
4 Severe overall disability PCPC=4; possibility of severe disability from non-cerebral systems dysfunction alone or with cerebral system
dysfunction; conscious but dependent on others for activities of daily living support
5 Coma or vegetative state PCPC=5
6 Brain death PCPC=6
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DATA COLLECTION AND CATEGORIZATION
Data collected included demographic information, chromosomal
and major non-cardiac structural abnormalities, cardiac diagno-
sis, and surgery, Aristotle complexity score, need for re-operation,
CPR and ECMO parameters, complications during ECMO, and
hospital length of stay.
Patients were divided into three major categories, including E-
CPR, OR-ECMO, and LCOS-ECMO. Because of the diversity of
cardiac lesions and physiology, patients were grouped into: (a)
single ventricle lesions (patients with 1 functional ventricle); (b)
two-ventricle lesions; (c) primary myocardial disease (including
patients with heart transplantation); and (d) primary pulmonary
hypertension.
Complications during ECMO were categorized as follows: (a)
brain injury (clinical or electroencephalographic seizures, signif-
icant central nervous system hemorrhage including epidural or
subdural hematoma, subarachnoid hemorrhage and >Grade I
intraventricular hemorrhage, and infarction or diffuse ischemic
changes based on ultrasound or CT scan); (b) renal injury (serum
creatinine≥ 1.5 mg/dL or dialysis use via hemodialysis, contin-
uous venovenous hemodialysis or hemofiltration); (c) blood-
stream bacterial infection; (d) respiratory complications (venti-
lator associated pneumonia, acute respiratory distress syndrome,
pulmonary hemorrhage, or pneumothorax); (e) cardiac com-
plications (new arrhythmias that required treatment, CPR and
inotropic support); (f) gastrointestinal complications [gastroin-
testinal hemorrhage or hyperbilirubinemia (defined as serum con-
jugated bilirubin≥ 2 mg/dL or total bilirubin≥ 15 mg/dL)]; (g)
bleeding (cannulation or surgical site bleeding, hemothorax and
hemopericardium requiring intervention); (h) mechanical circuit
complications (air emboli, thrombus formation in the circuit,
breaks, or leaks developing in any part requiring circuit change
and oxygenator failure).
STATISTICAL ANALYSIS
All variables were assessed for normal distribution using the
Kolmogorov–Smirnov test. Normally distributed data are pre-
sented as mean± standard deviation. Data that were not nor-
mally distributed are presented as median with interquartile range
(IQR). Categorical variables are presented as the total number
followed by the percentage of the population in parenthesis. Cat-
egorical data were compared with the Fisher’s exact test or χ2 test
where appropriate and continuous data with the Wilcoxon test
for 2-group comparison or Kruskal–Wallis test for 3-group com-
parison. Due to the small number of patients in each individual
POPC scale, for statistical purposes and meaningful comparison,
patients with a POPC score 1 and 2 were considered one category
(Normal – mild disability group), and patients with POPC score
between 3 and 6 was a different category (moderate to severe dis-
ability group). All statistical analyses were performed with JMP
version 9.0 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Of the 95 patients placed on ECMO between January 2006 and
December 2010, 69 (73%) survived to hospital discharge and were
the cohort considered in this study. The median age and weight of
these patients was 47 days (IQR 8–500 days) and 4 kg (IQR 3–9 kg)
Table 3 | Demographics.
N =69
Age, days 47 (8, 500)
Weight, kg 4 (3, 9)
Corrected gestational age 40 (38, 42)
Sex, M (%) 40 (58)
Cardiac diagnosis
Single ventricle, n (%) 13 (19)
Two ventricle, n (%) 38 (55)
Primary myocardial disease, n (%) 15 (22)
Primary pulmonary HTN, n (%) 3 (4)
E-CPR, n (%) 30 (43)
OR-ECMO, n (%) 24 (35)
LCOS-ECMO, n (%) 15 (22)
Cardiac surgery before ECMO, n (%) 44 (64)





Chromosomal/structural abnormalities, n (%) 7 (10)
respectively. Complete demographics are summarized in Table 3.
Most patients in this cohort had undergone CPR and based on the
Aristotle level, the majority (53%) of the patients had a significant
disease complexity.
Pre-ECMO and during ECMO characteristics are presented in
Table 4. The CPR duration was 40 min (IQR 25–50 min). Though
22% of patients had a lactate> 10 before ECMO only 4% had
a lactate> 10 after the initiation of ECMO. At least one compli-
cation was documented in 42% of the patients (Table 5). Over-
all incidence of brain injury was 12%, which included seizures,
intracranial hemorrhage, and infarction.
DESCRIPTION OF OUTCOMES
Discharge and long-term neurodevelopmental outcomes for the
entire cohort are presented in Table 6. At hospital discharge, 52
(75%) patients had good – mild disability, and at the latest follow-
up this improved to 56 (81%) patients. Six (9%) died between
discharge and follow-up. Excluding the patients who died, overall
16 (23%) patients showed improvement in their neurologic sta-
tus and 3 (4%) showed deterioration. Of the patients who died,
one had severe Ebstein’s anomaly and the other five were surgi-
cal patients. Three of them had single ventricle anatomy and died
after Norwood and prior to the Glenn procedure, one had long
standing tetralogy of Fallot and Alagille syndrome in conjunction
with end-stage liver disease, and one died after receiving a heart
transplant with septicemia.
Comparison of the patients with good – mild disability vs. mod-
erate – severe neurologic disability at hospital discharge and at the
latest follow-up is shown in Tables 7 and 8. At hospital discharge
more patients with moderate to severe disability had undergone
CPR, plasma exchange and had intracranial insult. However, at the
latest follow-up, only the presence of cerebral infarction differed
between the groups.
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Table 4 | Pre and during – ECMO parameters.
N =69
CPR duration, min 40 (25, 50)
Categorized arterial blood gas pH
pH 7.39 (7.27, 7.52)
pH<7.21, n (%) 11 (16)
Categorized lactate
Lactate 4 (2, 10)
Lactate>5, n (%) 27 (39)
Lactate>10, n (%) 15 (22)
Epinephrine, µg/kg/min 0.1 (0.03, 0.15)
ECMO flow at 4 h, mL/kg/min 131 (97, 154)
ECMO flow at 24 h, mL/kg/min 115 (82, 143)
Categorized ABG – pH
pH 7.5 (7.33, 7.55)
pH<7.21, n (%) 2 (3)
Categorized lactate
Lactate 3 (2, 5)
Lactate>5, n (%) 12 (17)
Lactate>10, n (%) 3 (4)
Temperature at 4 h 35.8 (34.8, 36.5)
Temperature at 24 h 36.2 (35.4, 36.7)
Plasma exchange, n (%) 6 (9)
ECMO duration, h 46 (25, 87)
Post-ECMO EF 2 (1, 3)
Redo cardiac surgery, n (%) 2 (3)
Invasive interventions, n (%) 5 (7)
Hospital duration, days 41 (26, 57)
Table 5 | Incidence of complications.
Patients with at least 1 complication, n (%) 29 (42)
Brain injury, n (%) 8 (12)
Seizures, n (%) 4 (6)
CNS hemorrhage, n (%) 2 (3)
CNS infarct, n (%) 2 (3)
Renal dysfunction, n (%) 16 (23)
Bloodstream infection, n (%) 4 (6)
ECMO support 23 (33)
Oxygenator failure, n (%) 4 (6)
Thrombus in ECMO circuit, n (%) 9 (13)
Cannula, surgical site, other bleeding, n (%) 10 (15)
Respiratory
Pulmonary hemorrhage, n (%) 0
Pneumothorax, n (%) 1 (1.5)
Cardiac
Arrhythmias on ECMO, n (%) 1 (1.5)
CPR on ECMO, n (%) 0
Inotropes on ECMO, n (%) 7 (10)
Gastrointestinal
Hyperbilirubinemia, n (%) 8 (12)
DISCUSSION
This report represents the neurological outcomes of 69 cardiac
ECMO patients at an advanced cardiac ECMO center. Eighty-one
Table 6 | Neurodevelopmental outcomes.
POPC scale at hospital discharge
Interval time from ECMO, days 35 (18, 47)
Good, n (%) 39 (57)
Mild disability, n (%) 13 (19)
Mod disability, n (%) 12 (17)
Severe disability, n (%) 4 (6)
Coma or vegetative, n (%) 1 (1)
POPC scale at latest follow-up
Interval time from ECMO, years 1.7 (1, 4)
Good, n (%) 42 (61)
Mild disability, n (%) 14 (20)
Mod disability, n (%) 6 (9)
Severe disability, n (%) 1 (1)
Coma, n (%) 0
Death, n (%) 6 (9)
Table 7 | Comparison of patients with good – mild vs.









Cardiac surgery, n (%) 35 (67) 9 (53) 0.28
Single ventricle 12 (23) 1 (6) 0.1
Aristotle level 4 21 (40) 3 (18) 0.3
E-CPR, n 18 (34) 12 (70) 0.009
CPR duration>50 min 5 (10) 0 0.01
Pre-ECMO pH<7.21 7 (13) 4 (23) 0.32
Pre-ECMO lactate>10 9 (21) 5 (29) 0.5
Chromosomal Abn 5 (10) 2 (12) 0.8
ECMO parameters
ECMO flows>180 3 (7) 0 0.3
pH<7.21 2 (4) 0 0.4
Lactate>10 2 (4) 1 (6) 0.7
Seizures 2 (5) 2 (12) 0.3
Infarct 0 2 (12) 0.009
Hemorrhage 0 2 (12) 0.009
Renal injury 7 (30) 8 (53) 0.2
Plasma exchange 2 (4) 4 (23) 0.01
percent of the surviving patients had normal to mild neurologi-
cal impairment at the latest follow-up nearly 2 years after ECMO
support, while 19% showed significant neurological impairment
(including death). The most significant parameters that appeared
to increase risk for poor neurological outcome were presence of
CPR, cerebral infarction or hemorrhage, and the use of plasma
exchange. Though the latter one likely represents a group of
patients who were sicker and thus needing plasma exchange, how-
ever we cannot be definitive that the actual procedure itself wasn’t
associated more complications and therefore worsening neuro-
logic disability. Our results are similar to the 14% of children who
were found to have major neurological impairment (not explained
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Table 8 | Comparison of patients with good – mild vs.









Cardiac surgery, n (%) 37 (66) 7 (54) 0.5
Single ventricle 9 (16) 4 (31) 0.2
Aristotle level 4 19 (72) 5 (38) 0.7
E-CPR 24 (43) 6 (46) 0.8
CPR duration>50 min 5 (9) 0 0.5
Pre-ECMO pH<7.21 7 (13) 4 (31) 0.2
Pre-ECMO lactate>10 12 (25) 2 (18) 0.9
Chromosomal Abn 5 (9) 2 (15) 0.6
ECMO parameters
ECMO flows>180 2 (4) 1 (10) 0.5
pH<7.21 2 (4) 0 0.8
Lactate>10 1 (2) 2 (15) 0.1
Seizures 2 (4) 2 (17) 0.2
Infarct 0 2 (15) 0.03
Hemorrhage 2 (4) 0 0.9
Renal injury 11 (35) 4 (57) 0.4
Plasma exchange 4 (7) 2 (15) 0.3
by a chromosomal disorder) at 5 years of age in a multi-center
study in Europe and the UK randomized control trial, but less than
reported elsewhere (11, 17–19). One important difference with our
center compared to the data published elsewhere, is the duration of
ECMO averaged <48 h (maximally 87 h), whereas other reports
show an average of over 100 h ECMO duration (17, 19). Since
ECMO can be associated with so many disastrous complications,
we as a group are strong proponents of shortening ECMO dura-
tion in the hopes of minimizing complications even at the expense
of low to medium doses of inotropic and respiratory support.
Overall it is difficult to determine whether the underlying eti-
ology and cardiac anatomy is more of a significant contributor
to the neurological outcomes of patients, or whether the actual
course of ECMO itself is more of a significant contributor; particu-
larly with respect to the varying anticoagulation protocols utilized
by every center and the common issue of maintaining the target
parameters within one’s own protocol. A recent review of the anti-
coagulation parameters of ECMO patients at our institution over
a 5-year period showed that 93% of the recorded high-range ACT
(Hemochron ACT+) values were<180 s, which could conceivably
contribute to the formation of thromboemboli (9). A recent sur-
vey of our ACT data from 2010 until 2013 indicates that 50% of the
ACT data are outside the normally accepted range of 180–220 s for
the low-range ACT (Hemochron ACT-LR). Ultimately, it may be
a combination of the pre-ECMO etiology, which increases risk for
poor neurologic outcomes and ECMO complications and then the
during ECMO complications (particularly the coagulation status)
that determines the composite risk for neurologic injury.
However irrespective of the nature of neurologic injury, this
study as well as our previous ECMO survival study (1) show
that while superior survival is feasible, neurologic insult can be
reduced and that neurologic improvement over the long run is
expected. This highlights the importance and investment into early
neurodevelopmental intervention for these children.
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